<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00588068</url>
  </required_header>
  <id_info>
    <org_study_id>00-109</org_study_id>
    <nct_id>NCT00588068</nct_id>
  </id_info>
  <brief_title>Molecular Characterization of Neuroblastic Tumor: Correlation With Clinical Outcome</brief_title>
  <official_title>Molecular Characterization of Neuroblastic Tumor: Correlation With Clinical Outcome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Memorial Sloan Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Southern Illinois University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Spanish National Cancer Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>St. Jude Children's Research Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Washington University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Texas</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Weill Medical College of Cornell University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Memorial Sloan Kettering Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to find out the genetic and biochemical makeup of your
      neuroblastic tumor, which influences its aggressiveness and the suitable therapy. These
      research studies include surface marker analysis, cytogenetics, cancer genes,genome
      sequencing, tumor growth-related genes and tumor growth in test tubes. Your blood, marrow,
      and hematopoietic stem cell samples will also be tested for tumors or leukemia cells, and
      your serum tested for anti-tumor antibodies.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To collect tumor, marrow specimens prospectively to study the molecular-genetic makeup of
      individual neuroblastic tumor and its metastasis by blood and marrow, and to correlate these
      findings with clinical outcome, and to relate the signaling circuitry of neuroblastic tumors
      to that of embryonic neuroectodermal cells. .
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 26, 2000</start_date>
  <completion_date type="Anticipated">September 2018</completion_date>
  <primary_completion_date type="Anticipated">September 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>To study the molecular-genetic makeup and metastasis of neuroblastic tumors.</measure>
    <time_frame>2 years</time_frame>
    <description>Before surgery a maximum of 5 blood drawings (20-30 ml) will be performed per year (at least one month apart) per patient</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To study the correlation of these biologic markers with clinical outcome.</measure>
    <time_frame>2 years</time_frame>
    <description>Before surgery and a maximum of 5 blood drawings (20-30 ml) will be performed per year (at least one month apart) per patient</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To relate neuroblastic tumor and embryonic neuroectodermal cell circuitry.</measure>
    <time_frame>2 years</time_frame>
    <description>Up to six fetal adrenal samples will be obtained (without patient identifiers) from gestational week 20, when neuroblasts are present and thought to be differentiating within the fetal adrenal gland.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">1500</enrollment>
  <condition>Neuroblastoma</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <description>Tumor and Marrow Markers</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Tumor and Marrow Markers</intervention_name>
    <description>Tumor and Marrow Markers</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Tumor, marrow and blood samples
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients will be offered participation in this study by their attending oncologist in the
        Department of Pediatrics at Memorial Sloan Kettering Cancer Center.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Neuroblastic tumors diagnosed in accordance with the International Neuroblastoma
             Staging System

        OR

          -  Clinically suspected neuroblastic tumors.

        Exclusion Criteria:
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nai-Kong Cheung, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nai-Kong Cheung, M.D., Ph.D.</last_name>
    <phone>646-888-2313</phone>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Shakeel Modak, MD</last_name>
    <phone>212-639-7623</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nai-Kong Cheung, M.D., Ph.D.</last_name>
    </contact>
    <investigator>
      <last_name>Nai-Kong Cheung, M.D., Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mskcc.org</url>
    <description>Memorial Sloan Kettering Cancer Center website</description>
  </link>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 24, 2007</study_first_submitted>
  <study_first_submitted_qc>January 7, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 8, 2008</study_first_posted>
  <last_update_submitted>March 27, 2018</last_update_submitted>
  <last_update_submitted_qc>March 27, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 29, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Adrenal Gland</keyword>
  <keyword>No stage requirement</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neuroblastoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

